The Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia (ACCURATE) Study

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Diagnostic Test
Study Type: Interventional
Study Phase: Not Applicable

ACCURATE will test the hypothesis that opportunistic genetic testing for Familial Hypercholesterolemia (FH) in patients admitted to hospital with an acute coronary syndrome will increase the diagnosis of FH and will impact patient care and outcomes. The study will recruit patients admitted to hospital with an acute coronary syndrome, and research-based genetic testing will be conducted for known FH-causing genetic variants. The results will be returned to the patients' treating physicians. The primary endpoint will be the number of patients with a new diagnosis of FH. The secondary endpoints will be the proportion of patients who undergo intensification of lipid-lowering therapy, the lowest LDL cholesterol level achieved, and the proportion of patients reaching guideline recommended lipid targets in the 12 months after the index acute coronary syndrome.

Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: No

• Age <60 years


• Admitted to an acute cardiac unit with either:

• A ST elevation myocardial infarction (STEMI), or

• A non-ST elevation myocardial infarction (NSTEMI)


• Maximum lipid level at the time of admission or during the prior 1 year of

• LDL level ≥4 mmol/L (154 mg/dL) if not on a statin, or

• LDL-C level ≥2.5 mmol/L (96 mg/dL) if on a statin prior to presentation, or

• Non-HDL-C ≥4.6 mmol/L (177 mg/dL) if LDL-C not available

Other Locations
St.Pauls Hospital
Vancouver General Hospital
Contact Information
Lubomira Cermakova, MSc
Navid Saleh
Time Frame
Start Date: January 1, 2022
Estimated Completion Date: June 2023
Target number of participants: 250
No Intervention: Observation
Those admitted in the first 6 months of the study that meet the inclusion criteria. Patients will be treated according to the normal standard of care for acute coronary syndrome.
Experimental: Active-testing
Those admitted between 6-18 months of the study meeting the inclusion criteria. Saliva samples will be collected for DNA testing.
Collaborators: Genome British Columbia, Vancouver Coastal Health Research Institute
Leads: University of British Columbia

This content was sourced from

Similar Clinical Trials